Skip to main content

Table 4 Univariate survival analysis of anthracycline- and CMF-treated subgroups, N = 99 and N = 324*

From: Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

   DFS   OS  
   HR (95% CI) P HR (95% CI) P
Anthracycline-treated patients TIMP-1
(continuous variable)
1.66 (0.96-2.85) 0.07 3.52 (1.54-8.06) 0.003
  TIMP-1
(high vs. low)
1.52 (0.88-2.63) 0.13 2.53 (1.19-5.39) 0.02
CMF-treated patients TIMP-1
(continuous variable)
1.12 (0.84-1.51) 0.44 1.22 (0.82-1.81) 0.32
  TIMP-1
(high vs. low)
1.15 (0.82-1.61) 0.42 1.44 (0.91-2.29) 0.12
  1. * Analyses stratified for hormone receptor status, nodal status and RT on the axilla.